Mark R. Bamforth is Director at PEREGRINE PHARMACEUTICALS INC (PPHM). They have made 9 open-market trades across 3 companies since 2008, most recently 2021-03-17.
CIK 0001435745
6 open-market purchases totalling $2.9M since 2009, against 3 sales. Across 5 scored buys the stock is up 1.3% at thirty days, and 2.6 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 20% | 40% | — |
| Avg Move | +2.5% | +1.3% | — |
| Alpha | +0.8% | -2.6% | — |
| Scored | 5 | 5 | 3 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CDMO | BUY | 2021-03-17 | 2021-03-19 | $18.18 | $2.3M | -0.8% | +3.5% | +29.1% |
| CDMO | SELL | 2021-03-17 | 2021-03-19 | $18.18 | $2.3M | -0.8% | +3.5% | +29.1% |
| CDMO | BUY | 2020-03-13 | 2020-03-16 | $4.01 | $104K | +31.0% | +8.7% | +58.6% |
| CDMO | BUY | 2018-02-15 | 2018-02-20 | $2.25 | $113K | -6.5% | -3.8% | +32.7% |
| PPHM | BUY | 2017-10-27 | 2017-10-27 | $4.51 | $162K | -5.5% | -1.1% | N/A |
| PPHM | BUY | 2017-10-27 | 2017-10-27 | $4.50 | $235K | -5.5% | -1.1% | N/A |
| GENZ | BUY | 2009-03-04 | 2009-03-06 | $54.54 | $38K | N/A | N/A | N/A |
| GENZ | SELL | 2008-08-14 | 2008-08-15 | $81.71 | $1.6M | N/A | N/A | N/A |
| GENZ | SELL | 2008-08-06 | 2008-08-07 | $79.00 | $509K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.